Ulcerative colitis, N Engl J Med, vol.365, pp.1713-1725, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01707812
Ulcerative colitis, Lancet Lond Engl, vol.389, pp.1756-1770, 2017. ,
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT TM registry, Am J Gastroenterol, vol.107, pp.1409-1422, 2012. ,
Risk factors for opportunistic infections in patients with inflammatory bowel disease, Gastroenterology, vol.134, pp.929-965, 2008. ,
Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. Dig Liver Dis Off, J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.51, pp.236-241, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02420202
Systematic review with network meta-analysis: firstand second-line pharmacotherapy for moderate-severe ulcerative colitis, Aliment Pharmacol Ther, vol.47, pp.162-175, 2018. ,
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.17, pp.838-846, 2019. ,
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis, United Eur Gastroenterol J, vol.8, pp.91-98, 2019. ,
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.14, pp.1593-1601, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01278611
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicenter cohort study ,
, Aliment Pharmacol Ther, 2017.
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study, Aliment Pharmacol Ther, vol.50, pp.40-53, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02362791
Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, vol.353, pp.2462-2476, 2005. ,
Reliability and initial validation of the ulcerative colitis endoscopic index of severity, Gastroenterology, vol.145, pp.987-995, 2013. ,
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis, N Engl J Med, vol.381, pp.1201-1214, 2019. ,
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target ,
URL : https://hal.archives-ouvertes.fr/hal-01191653
, Am J Gastroenterol, vol.110, pp.1324-1338, 2015.
Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study, Inflamm Bowel Dis, vol.23, pp.833-839, 2017. ,
Ustekinumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, vol.375, pp.1946-60, 2016. ,
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease, Aliment Pharmacol Ther, vol.47, pp.896-905, 2018. ,
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR), J Drugs Dermatol JDD, vol.14, pp.706-714, 2015. ,
Effectiveness and safety of Ustekinumab for Crohn's disease ,
, systematic review and pooled analysis of real-world evidence, Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.51, pp.1232-1240, 2019.
The safety of ustekinumab for the treatment of psoriatic arthritis, Expert Opin Drug Saf, vol.16, pp.733-742, 2017. ,